Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Income from Continuing Operations: 2012-2024

Historic Income from Continuing Operations for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to $28.5 million.

  • Coherus Oncology's Income from Continuing Operations rose 6.47% to -$44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.0 million, marking a year-over-year increase of 124.40%. This contributed to the annual value of $28.5 million for FY2024, which is 111.98% up from last year.
  • Latest data reveals that Coherus Oncology reported Income from Continuing Operations of $28.5 million as of FY2024, which was up 111.98% from -$237.9 million recorded in FY2023.
  • In the past 5 years, Coherus Oncology's Income from Continuing Operations ranged from a high of $132.2 million in FY2020 and a low of -$291.8 million during FY2022.
  • Its 3-year average for Income from Continuing Operations is -$167.0 million, with a median of -$237.9 million in 2023.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first slumped by 317.16% in 2021, then soared by 111.98% in 2024.
  • Yearly analysis of 5 years shows Coherus Oncology's Income from Continuing Operations stood at $132.2 million in 2020, then plummeted by 317.16% to -$287.1 million in 2021, then fell by 1.62% to -$291.8 million in 2022, then grew by 18.46% to -$237.9 million in 2023, then soared by 111.98% to $28.5 million in 2024.